Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Drops Restricted Access Requirement For Amgen’s Nplate And GSK’s Promacta

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s decision to modify the risk program for thrombocytopenia treatments may influence CMS to drop Nplate from its list of potential National Coverage Determinations.

You may also be interested in...

GSK’s Promacta Adds ‘Breakthrough’ Claim On Strength Of Small NIH Study

Supplemental approval for severe aplastic anemia, a “breakthrough” designation, was based on a single-center, open-label Phase II trial in 43 patients that was conducted by the National Heart, Lung and Blood Institute.

REMS Modification Studies Could Use Foreign Markets As Controls

A look at the safety record of a drug in foreign countries where REMS elements are not in play could differentiate the impact of a REMS compared to other risk management efforts, Amgen suggests.

Avandia Re-Adjudication Might Result In “Refreshing” Restricted Distribution Roll Back

More than half of a 26-member advisory committee supports eliminating or easing the REMS for GSK’s diabetes drug, but the spilt vote and high-profile of the product’s safety issues suggest that FDA is unlikely to modify Avandia’s risk management.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts